MedTrace Logo

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy

NCT01407471 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-07-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.

Conditions

  • Cutaneous Atrophy Due to Corticosteroids

Interventions

DRUG

Clobetasol + Spironolactone

One application 6 days a week during 4 weeks

DRUG

Clobetasol + Placebo

One application 6 days a week during 4 weeks

DRUG

Placebo + Spironolactone

One application 6 days a week during 7 weeks

DRUG

Placebo + Placebo

One application 6 days a week during 7 weeks

Sponsors & Collaborators

  • Société de Dermatologie Française

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Eve MAUBEC, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01407471 on ClinicalTrials.gov